Last reviewed · How we verify
NCT06627907: FC_EEOT
Hemodynamic Response to the End-expiratory Occlusion Test to Titrate Fluid Challenge in Operating Room.
trial testing fluid challenge in Fluid Responsiveness Predictability in 300 participants. Not yet recruiting.
1 June 2026
Quick facts
| Lead sponsor | Humanitas Clinical and Research Center |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 November 2024 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 September 2026 |
Drugs / interventions tested
- fluid challenge — full drug profile →
- end-expiratory occlusion test
Conditions studied
- Fluid Responsiveness Predictability — all drugs for Fluid Responsiveness Predictability →
Sponsor
Humanitas Clinical and Research Center
Who can join
18 and older, any sex, with Fluid Responsiveness Predictability. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Personalzing intraoperative anesthetic fluid management may help in preventing fluid accumulation and related complications. Fluids are gine as boluses in operating room (the so-called FC). The response to the FC is due to several physiological conditions related to the "preload dependency" (i.e. the intrinsic ability of the heart of increasing the stroke volume - SV - in response to fluid administration). The minimal volume required to appropriately "challenge" the cardiovascular system is 4 ml/kg of fluid, but higher volumes (up to 6 ml/kg may be needed). Predicting the response to FC administration may be possible by applying a physiological test (called functional hemodynamic test), such as the end-expiratory occlusion test, consisting in interrupping the mechanical ventilation and hence promoting venous return and consequente SV changes. The percentage of SV increase associated to EEOT may predict fluid responsiveness to the FC (patients responders will increase SV to a bigger extent, as compared to non-responders)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06627907
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of fluid challenge
Trials testing the same drug.
- NCT06839404 — Pharmacodynamic Analysis of the HaemOdynamic Effects of a Standard Fluid BolUS · recruiting
- NCT03810118 — Fluid Challenge Infusion and Response · NA · completed
- NCT02894996 — Does the Response to a Mini-fluid Challenge of 3ml/kg in 2 Minutes Predict Fluid Responsiveness for Pediatric Patient? · NA · completed
Other Humanitas Clinical and Research Center trials
Trials by the same sponsor.
- NCT07161297 — Remimazolam for Colonoscopy in IBD Patients · Phase 4 · not yet recruiting
- NCT04934943 — "Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools" · not yet recruiting
- NCT06394947 — Fluid Challenge in Intensive Care The FENICE II Study · completed
- NCT06099171 — Therapy With Paravertebral Oxygen-ozone Injections and Topical Cannabidiol and β-Caryophyllene Patch in Neck Pain · Phase 3 · unknown
- NCT06691061 — The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06627907 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Humanitas Clinical and Research Center
- Last refreshed: 8 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06627907.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing